论文部分内容阅读
目的探讨miR-29b与β受体阻滞剂的关系及其对马凡氏综合征(MFS)发病的影响。方法选择MFS患者25例(A组,5例来自两个不同的MFS家系)和MFS未发病亲属8例(B组);对照组为健康志愿者25例(C组)。用实时定量PCR检测三组miR-29b的表达水平。25例MFS患者中,10例用β受体阻滞剂治疗。结果 A组miR-29b表达高于C组(P<0.01);B组miR-29b表达低于A组,但高于C组(P<0.05)。用β受体阻滞剂治疗者miR-29b表达低于未治疗者(P<0.05)。结论 MFS患者的miR-29b表达增高,β受体阻滞剂可降低患者的miR-29b表达,延缓其疾病进展。
Objective To investigate the relationship between miR-29b and β-blockers and its effect on the incidence of Mäffy’s syndrome (MFS). Methods Twenty-five MFS patients (group A, 5 from two different MFS families) and 8 non-MFS relatives (group B) were selected. The control group consisted of 25 healthy volunteers (group C). Real-time quantitative PCR was used to detect the expression levels of miR-29b in three groups. Of 25 MFS patients, 10 were treated with beta blockers. Results The expression of miR-29b in group A was higher than that in group C (P <0.01). The expression of miR-29b in group B was lower than that of group A, but higher than that of group C (P <0.05). MiR-29b expression was lower in patients treated with beta-blocker than in those without treatment (P <0.05). Conclusion The expression of miR-29b is increased in patients with MFS, and β-blockers reduce the expression of miR-29b and delay the progression of the disease.